Olfen (Diclofenac) is NOT Contraindicated in G6PD Deficiency
Diclofenac can be safely used in patients with G6PD deficiency, as there is no established contraindication for NSAIDs in this population. While one case report documents hemolysis following diclofenac administration in a G6PD-deficient patient, the evidence suggests this was likely multifactorial rather than a direct drug effect.
Evidence Analysis
Case Report Context
A single case report 1 describes a 16-year-old male with G6PD deficiency who developed severe hemolysis after receiving diclofenac sodium suppository (50 mg). However, critical analysis reveals:
- The patient had concurrent fever and infection at presentation
- Both infection and fever are well-established triggers for hemolysis in G6PD deficiency
- The hemolytic episode was attributed to the combination of infection and medication, not diclofenac alone
- This represents the only documented case linking diclofenac to G6PD-related hemolysis in the medical literature
Real-World Safety Data
Large-scale real-world evidence 2 from 31,962 G6PD-deficient patients demonstrated:
- Only 71 cases (0.2%) of major hemolysis requiring hospitalization over 12 years
- 71.8% were caused by fava beans
- 8.5% were associated with infection
- Only 4.2% (3 cases) were potentially medication-related (nitrofurantoin, phenazopyridine, and an unspecified "pain killer")
- No cases of hemolysis were attributed to NSAIDs including diclofenac
Guideline Classification
The most recent CPIC guideline 3 systematically reviewed medications implicated in G6PD deficiency and classified them by risk level. NSAIDs, including diclofenac, are not listed among high-risk, medium-risk, or even low-risk medications requiring special precautions in G6PD-deficient patients.
Clinical Implications
When to Use Diclofenac in G6PD Deficiency
- Standard dosing and precautions apply - no dose adjustment needed
- Monitor for typical NSAID adverse effects (cardiovascular, gastrointestinal) per standard guidelines 4
- No routine hemolysis monitoring required specifically for G6PD status
True Contraindications in G6PD Deficiency
The evidence clearly identifies medications that ARE contraindicated:
- Rasburicase - absolute contraindication 5
- Methylene blue - should be avoided; can cause severe hemolysis 6
- Primaquine - requires caution; Mediterranean variants (B-) have very high hemolysis risk 7, 8
Common Pitfalls to Avoid
- Do not confuse oxidative stress triggers: Infection and fever are the primary hemolysis triggers in G6PD deficiency, not NSAIDs
- Do not extrapolate from methylene blue: The fact that methylene blue causes hemolysis in G6PD deficiency does not mean all medications do
- Do not rely on single case reports: The isolated diclofenac case had confounding factors (concurrent infection/fever)
Practical Approach
For patients with known G6PD deficiency requiring analgesia/anti-inflammatory therapy:
- Diclofenac and other NSAIDs can be prescribed without restriction
- Focus on standard NSAID risk assessment (cardiovascular disease, GI bleeding risk, renal function) 4, 9
- Educate patients about true hemolysis triggers: fava beans, infections, and specific high-risk medications (rasburicase, methylene blue, certain antimalarials)
The absence of diclofenac from comprehensive G6PD medication risk classifications 3 and the lack of hemolysis cases in large real-world cohorts 2 provide strong reassurance for its safe use in this population.